Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts
highlighting data from its oncology portfolio will be presented at the
upcoming 2019 American Society of Clinical Oncology (ASCO) Annual
Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and
the 24th Congress of the European Hematology Association
(EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.

Abstracts accepted for presentation at ASCO feature genomic profiling
data from Incyte’s ongoing Phase 2 FIGHT-202 trial evaluating its
selective fibroblast growth factor receptor (FGFR) inhibitor,
pemigatinib, in patients with cholangiocarcinoma, as well as efficacy
and safety data from the Novartis-sponsored GEOMETRY mono-1 trial
of capmatinib, the investigational selective MET inhibitor licensed to
Novartis by Incyte. Additionally, data to be presented at EHA will
showcase the continued study of Incyte’s JAK1/JAK2 inhibitor,
ruxolitinib, in myeloproliferative neoplasms (MPNs).

“Our presence at ASCO and EHA illustrates Incyte’s ongoing commitment to
discovering and developing therapeutic options that address significant
unmet medical needs for patients,” said Steven Stein, M.D., Chief
Medical Officer, Incyte. “We are pleased to highlight new data on two
investigational medicines – pemigatinib and capmatinib – that were
discovered by Incyte scientists and for which we anticipate applications
for initial U.S. regulatory approvals later this year, as well as data
that furthers our understanding of the treatment of MPNs.”

Key ASCO and EHA abstracts include:

ASCO Abstracts

Oral Presentation

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell
lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1
(Abstract #9004, oral abstract session)

  • Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1

Poster Presentation

Comprehensive genomic profiling in FIGHT-202 reveals the landscape
of actionable alterations in advanced cholangiocarcinoma
#4080, poster session)

  • Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A

EHA Abstracts

Poster Presentations

Impact of myeloproliferative neoplasms (MPNS) and perceptions of
treatment goals amongst physicians and patients in 6 countries: an
expansion of the MPN Landmark Survey
(Abstract #PF681, poster

  • Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area

Real-world safety data from a non-interventional long-term post
authorization safety study of ruxolitinib in myelofibrosis
#PF679, poster presentation)

  • Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area

Safety and efficacy of ruxolitinib (RUX) in patients with
myelofibrosis (MF) and anemia (hemoglobin <10g/dL):
at Week 24 of the REALISE trial
(Abstract #PS1465, poster

  • Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area

For full session details and data presentation listings, please see the
and EHA (
online programs.

Where the use of compounds described herein is either investigational or
being studied for (a) new use(s), efficacy and safety have not been
established, and there is no guarantee that such compounds will become
commercially available for the use(s) under investigation.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte, please
visit the Company’s website at

Follow @Incyte on Twitter at

Forward-Looking Statements

Except for the historical information set forth herein, the matters set
forth in this press release, including statements regarding the
Company’s development pipeline and whether or when any development
compounds will be approved for use in humans anywhere in the world, its
presentation plans for the upcoming ASCO and EHA annual meetings and its
goal of improving the lives of patients, contain predictions, estimates
and other forward-looking statements. These forward-looking statements
are based on the Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments and the risks related to the
efficacy or safety of the Company’s development pipeline, the results of
further research and development, the high degree of risk and
uncertainty associated with drug development, clinical trials and
regulatory approval processes, other market or economic factors and
competitive and technological advances; and other risks detailed from
time to time in the Company’s reports filed with the Securities and
Exchange Commission, including its Form 10-Q for the quarter ending
March 31, 2019. Incyte disclaims any intent or obligation to update
these forward-looking statements.


Catalina Loveman
+1 302 498 6171

Michael Booth, DPhil
+1 302 498 5914

Thank you for donating to

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation